Stock 2196 SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Equities

2196

CNE100001M79

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:22 2024-04-29 am EDT 		5-day change 1st Jan Change
12.38 HKD +0.98% Intraday chart for Shanghai Fosun Pharmaceutical (Group) Co., Ltd. +4.74% -27.18%
Apr. 24 Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator MT
Apr. 18 China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy MT

Evolution of the average Target Price on Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Price target over the last 5 years

History of analyst recommendation changes

c6a08d9ef8383b0d3fc807235b.WX_pmd56SL-6_kE2HUsUmO9YoEZv_uYOooP5WmsjXfc.GAeF-Os2LsbTyBRGZxxg-5g1yRkJqrBvl--IGSRuLZ4_BqHs7Tsf69aQNg~b53786b84c3eb94b2e414012a5140e6e

Analyst Recommendations on Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Shanghai Fosun Pharmaceutical : Fosun Pharma’s MSCI ESG Rating Upgraded to A PU
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
8
Last Close Price
23.71 CNY
Average target price
29.75 CNY
Spread / Average Target
+25.47%
High Price Target
35 CNY
Spread / Highest target
+47.62%
Low Price Target
24.5 CNY
Spread / Lowest Target
+3.33%

Consensus detail

Consensus revision (last 18 months)

Ratings for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 600196 Stock
  4. 2196 Stock
  5. Consensus Shanghai Fosun Pharmaceutical (Group) Co., Ltd.